• Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line).
  
• Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Thr790Met (c.2369C>T); ClinVar=VCV000016613; Zygosity=Unspecified; Note=Responsible for gefitinib resistance (PubMed=20118985).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line).
  

PubMed=20118985; DOI=10.1038/onc.2009.526; PMCID=PMC2859699
Ercan D., Zejnullahu K., Yonesaka K., Xiao Y., Capelletti M., Rogers A., Lifshits E., Brown A., Lee C., Christensen J.G., Kwiatkowski D.J., Engelman J.A., Janne P.A.
Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor.
Oncogene 29:2346-2356(2010)

PubMed=26828195; DOI=10.1038/nm.4040; PMCID=PMC4900892
Hata A.N., Niederst M.J., Archibald H.L., Gomez-Caraballo M., Siddiqui F.M., Mulvey H.E., Maruvka Y.E., Ji F., Bhang H.-e.C., Krishnamurthy Radhakrishna V., Siravegna G., Hu H.-C., Raoof S., Lockerman E.L., Kalsy A., Lee D., Keating C.L., Ruddy D.A., Damon L.J., Crystal A.S., Costa C., Piotrowska Z., Bardelli A., Iafrate A.J., Sadreyev R.I., Stegmeier F., Getz G., Sequist L.V., Faber A.C., Engelman J.A.
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.
Nat. Med. 22:262-269(2016)